Alkermes (Alkermes) Accounts Payable & Accrued Expense

: $421 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

Alkermes's quarterly accounts payable & accrued expense increased from Jun. 2023 ($406 Mil) to Sep. 2023 ($414 Mil) and increased from Sep. 2023 ($414 Mil) to Dec. 2023 ($421 Mil).

Alkermes's annual accounts payable & accrued expense increased from Dec. 2021 ($368 Mil) to Dec. 2022 ($393 Mil) and increased from Dec. 2022 ($393 Mil) to Dec. 2023 ($421 Mil).

Alkermes Accounts Payable & Accrued Expense Historical Data

The historical data trend for Alkermes's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 300.97 [6] => 340.99 [7] => 368.45 [8] => 393.12 [9] => 421.10 )

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

300.97

340.99

368.45

393.12

421.10

Alkermes Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense																393.12	424.71	405.73	413.96	421.10

Alkermes Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Alkermes (Alkermes) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Executives

Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451